Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2011
At a glance
- Drugs Dalcetrapib (Primary)
- Indications Atherosclerosis; Coronary disorders; Hyperlipidaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 16 Jun 2011 Planned number of patients changed from 15 to 55.
- 16 Jun 2011 New trial record
- 01 May 2011 Results published in Clinical Drug Investigation.